Intravenous immunoglobulin increases plasma viscosity without parallel rise in blood pressure

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 3, 2012, Pages 286-290

  Bentley, P ^a   Rosso, M ^a   Sadnicka, A ^a   Israeli Korn, S ^a   Laffan, M ^b   Sharma, P ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

hypertension; intravenous immunoglobulin; stroke; therapeutics

Indexed keywords

ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; FIBRINOGEN; HOMOCYSTEINE; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 6;

ACUTE INFLAMMATORY DEMYELINATING POLYNEUROPATHY; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; BLOOD PRESSURE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; DRUG INFUSION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMATOCRIT; HUMAN; HYPERTENSION; INFLAMMATION; MALE; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; PLASMA VISCOSITY; PULSE PRESSURE; RISK FACTOR; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THROMBOSIS;

ADULT; AGED; ANTIBODIES, ANTICARDIOLIPIN; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; BIOLOGICAL MARKERS; BLOOD PRESSURE; BLOOD VISCOSITY; COHORT STUDIES; FEMALE; HOMOCYSTEINE; HUMANS; HYPERTENSION; IMMUNOGLOBULINS, INTRAVENOUS; INTERLEUKIN-6; LONDON; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THROMBOSIS; YOUNG ADULT;

EID: 84861332161     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01287.x     Document Type: Article

References (32)

1. Marketing Research Bureau (2009) The plasma fractions market in the United States-2009. Summary available at: (accessed 5 July 2011).
2. Hughes R, Donofrio P, Bril V, et al. (2008) Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurology, 7, 136-144.
3. Orbach H, Katz U, Sherer Y, Shoenfeld Y, (2005) Intravenous immunoglobulin: adverse effects and safe administration. Clinical Reviews in Allergy and Immunology, 29, 173-184.
4. Dalakas M, Clark W, (2003) Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record. Neurology, 60, 1736-1737.
5. Stangel M, Kiefer R, Pette M, Smolka MN, Marx P, Gold R, (2003) Side effects of intravenous immunoglobulins in neurological autoimmune disorders-a prospective study. Journal of Neurology, 250, 818-821.
6. Marie I, Maurey G, Hervé F, Hellot MF, Levesque H, (2006) Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. British Journal of Dermatology, 155, 714-721.
7. Dalakas M, (1994) High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology, 44, 223-226.
8. Kowal P, Zmylony A, (2008) Hemorheological changes after intravenous gammaglobulin administration in patients with neurological disorders. Clinical Hemorheology and Microcirculation, 40, 229-234.
9. Reinhart W, Berchtold P, (1992) Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet, 339, 662-664.
10. Reinhart WH, Lutolf O, Nydegger UR, Mahler F, Straub PW, (1992) Plasmapheresis for hyperviscosity syndrome in macroglobulinemia Waldenström and multiple myeloma: influence on blood rheology and the microcirculation. Journal of Laboratory and Clinical Medicine, 119, 69-76.
11. Pierce L, Jain N, (2003) Risks associated with the use of intravenous immunoglobulin. Transfusion Medicine Reviews, 17, 241-251.
12. Donofrio PD, Bril V, Dalakas MC, et al. (2010) Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy. Archives of Neurology, 67, 1082-1088.
13. Mendell JR, Barohn RJ, Freimer ML, et al. (2001) Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology, 56, 445-449.
14. Cinar Y, Demir G, Paç M, Cinar A, (1999) Effect of hematocrit on blood pressure via hyperviscosity. American Journal of Hypertension, 12, 739-743.
15. Cinar Y, Senyol A, Duman K, (2001) Blood viscosity and blood pressure: role of temperature and hyperglycemia. American Journal of Hypertension, 14, 433-438.
16. Fowkes F, Lowe G, Rumley A, Lennie S, Smith F, Donnan P, (1993) The relationship between blood viscosity and blood pressure in a random sample of the population aged 55 to 74 years. European Heart Journal, 14, 597-601.
17. Meiselman H, (1999) Hemorheologic alterations in hypertension: chicken or egg? Clinical Hemorheology and Microcirculation, 21, 195-200.
18. Salazar Vázquez BY, Martini J, Chávez Negrete A, et al. (2010) Cardiovascular benefits in moderate increases of blood and plasma viscosity surpass those associated with lowering viscosity: experimental and clinical evidence. Clinical Hemorheology and Microcirculation, 44, 75-85.
19. Tofler G, Muller J, (2006) Triggering of acute cardiovascular disease and potential preventive strategies. Circulation, 114, 1863-1872.
20. Caress J, Cartwright M, Donofrio P, Peacock JJ, (2003) The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology, 60, 1822-1824.
21. Bagdasarian A, Tonetta S, Harel W, Mamidi R, Uemura Y, (1998) IVIG adverse reactions: potential role of cytokines and vasoactive substances. Vox Sanguinis, 74, 74-82.
22. Aukrust P, Frland S, Liabakk N, et al. (1994) Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood, 84, 2136-2143.
23. Schuett H, Luchtefeld M, Grothusen C, Grote K, Schieffer B, (2009) How much is too much? Interleukin-6 and its signalling in atherosclerosis Thrombosis and Haemostasis, 102, 215-222.
24. Sherer Y, Wu R, Kraus I, Peter J, Shoenfeld Y, (2001) Antiphospholipid antibody levels in intravenous immunoglobulin (IVIg) preparations. Lupus, 10, 568-570.
25. Casas J, Bautista L, Smeeth L, Sharma P, Hingorani A, (2005) Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet, 365, 224-232.
26. Letcher R, Chien S, Pickering T, Laragh J, (1983) Elevated blood viscosity in patients with borderline essential hypertension. Hypertension, 5, 757-762.
27. Koenig W, Sund M, Ernst E, Matrai A, Keil U, Rosenthal J, (1989) Is increased plasma viscosity a risk factor for high blood pressure? Angiology, 40, 153-163.
28. Lip G, Blann A, Farooqi I, Zarifis J, Sagar G, Beevers D, (2001) Abnormal haemorheology, endothelial function and thrombogenesis in relation to hypertension in acute (ictus < 12 h) stroke patients: the West Birmingham stroke project. Blood Coagulation and Fibrinolysis, 12, 307-315.
29. Sztajzel R, Le Floch-Rohr J, Eggimann P, (1999) High-dose intravenous immunoglobulin treatment and cerebral vasospasm: a possible mechanism of ischemic encephalopathy? European Neurology, 41, 153-158.
30. Ciuffetti G, Schillaci G, Lombardini R, Pirro M, Vaudo G, Mannarino E, (2005) Plasma viscosity in isolated systolic hypertension: the role of pulse pressure. American Journal of Hypertension, 18, 1005-1008.
31. de Simone G, Devereux R, Chinali M, Best L, Lee E, Welty T, (2005) Association of blood pressure with blood viscosity in american indians: the strong heart study. Hypertension, 45, 625-630.
32. Ling Z, Yeoh E, Webb B, Farrell K, Doucette J, Matheson D, (1993) Intravenous immunoglobulin induces interferon-gamma and interleukin-6 in vivo. Journal of Clinical Immunology, 13, 302-309.